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ABSTRACT
Huntington’s disease (HD) is one of the chronic devastating neurodegenerative disorders. The
pathophysiological processes clearly involve both excitotoxicity and reduced gene 
transcription due to the decreased level of histone acetylation, accompanied by the loss of γ-
aminobutyric acidergic (GABAergic) medium-sized spiny neurons in the striatum as a 
pathological hallmark of HD. Thus, the antiepileptic drug valproate, which has proved 
GABAergic, antiexcitotoxic and histone deacetylase inhibitor effects, might be of value by 
exerting a beneficial neuroprotective effect. We have now tested this drug in the N171-82Q 
transgenic mouse model of HD, following its chronic intraperitoneal administration in a daily 
dose of 100 mg/kg. Valproate significantly prolonged the survival of the transgenic mice and 
significantly ameliorated their diminished spontaneous locomotor activity, without exerting 
any noteworthy side-effect on their behaviour or the striatal dopamine content at the dose 
administered. The beneficial effect of valproate is probably explained by its complex 
pharmacological activity. As several previous clinical trials carried out with valproate did not 
indicate any positive effect in HD, it is worth considering the design of new studies based on 
a well-planned treatment regime with higher dose, using valproate in monotherapy or in 
combination therapy with a high number of participating patients.
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INTRODUCTION
Huntington’s disease (HD) is an autosomal dominantly inherited neurodegenerative 
disorder manifested with cognitive, psychiatric and motor symptoms in middle-aged people. 
The motor symptoms include the loss of coordination of voluntary movements and the 
appearance of involuntary movements, such as chorea and dystonia. The disease displays a 
progressive nature, ending in death after a course of 15-20 years. The pathological alterations 
mainly affect the central nervous system and especially the striatum in which the loss of γ-
aminobutyric acidergic (GABAergic) medium-sized spiny neurons (MSNs) is the most 
pronounced feature (reviewed by Vécsei and Beal, 1996; Walker, 2007).
HD is caused by expansion of the cytosine-adenine-guanine (CAG) repeat in the gene 
coding for the N-terminal region of the huntingtin protein, which leads to the formation of a 
polyglutamine stretch. The gene was identified in 1993 (The Huntington’s Disease 
Collaborative Research Group, 1993), located on the short arm of chromosome 4 (4p16.3) and
labelled interesting transcript 15. The physiological HD alleles comprise 6 to 35 CAGs, while 
alleles with 36 to 39 CAGs are characterized by reduced penetrance. Above 39 CAGs, there is
obligatory disease development. The greater the expansion, the earlier the disease is 
manifested (reviewed by Gárdián and Vécsei, 2004).
The posttranslational acetylation of histones by histone acetyltransferases (HATs) at 
lysine residues results in the neutralization of those positively charged proteins, leading to a 
more open conformation of the DNA, allowing the binding of certain transcription factors. 
The histone deacetylases (HDACs) remove the acetyl groups, which results in a reduced 
ability to bind the transcription factors, and thus the transcription processes become 
considerably reduced. There is increasing evidence that an altered balance between HAT and 
HDAC activity may accompany the development of chronic neurodegenerative disorders, 
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including HD (reviewed by Langley et al., 2005; Sadri-Vakili and Cha, 2006). The mutant 
huntingtin protein can interact with proteins which regulate transcription (reviewed by Cha, 
2000; Kazantsev and Hersch, 2007), thereby deteriorating their normal function. One group of
these proteins is the HATs (Igarashi et al., 2003). The inhibition of HDACs might be able to 
restore the altered balance described above, as the application of such substances was found to
arrest the polyglutamine-dependent neurodegeneration in different models of polyglutamine 
disease (Steffan et al., 2001; Gárdián et al., 2005). Excitotoxicity may also play an important 
role in the development of HD (Coyle and Schwarcz, 1976; McGeer and McGeer, 1976; 
Vécsei and Beal, 1991) in addition to or combined with proved metabolic disturbances 
(Klivényi et al., 2000, 2004; reviewed by Sas et al., 2007). The loss of neurons expressing N-
methyl-D-aspartate (NMDA) receptors in an extremely large amount has been observed in the
human striatum (Young et al., 1988) and in transgenic models. The enhanced sensitivity of the
MSNs to NMDA treatment has also been described (Cepeda et al., 2001; Zeron et al., 2002; 
Shehadeh et al., 2006).
2-Propylpentanoic acid (valproate) is a widely used antiepileptic drug, although it is 
also applied in other indications, such as bipolar disorders, migraine and chronic neuropathic 
pain (reviewed by Johannessen and Johannessen, 2003). Its pharmacological action is exerted 
via a very complex mechanism (reviewed by Löscher, 1999; Kostrouchová et al., 2007). It 
can increase brain GABA levels (Taberner et al., 1980) through the reduction of GABA-
transaminase, increasing the glutamate decarboxylase activity (Löscher, 1981a, 1981b), and it 
can potentiate the release of GABA (Gram et al., 1988). Furthermore, valproate can suppress 
NMDA-evoked transient depolarizations (Zeise et al., 1991), and it can therefore exert a dose-
dependent neuroprotective effect against excitotoxicity (Hashimoto et al., 2002). Besides the 
effects detailed above, valproate can additionally influence multiple regulatory pathways. In 
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this manner, probably its most important effect is the inhibition of HDACs (Krämer et al., 
2003); it selectively inhibits the catalytic activity of class I HDACs and induces the 
proteasomal degradation of class II HDACs.
The aim of our experiments was to utilize a transgenic mouse model of HD to test the 
applicability of valproate, which has been demonstrated to be protective in the malonate 
model of HD (Morland et al., 2004), on the basis of its proved GABAergic, antiexcitotoxic 
and HDAC inhibitor (HDACi) effects. Moreover, we measured the striatal levels of dopamine
and two of its metabolites after chronic valproate administration, because valproate can exert 
effects on the brain dopamine concentrations (Vriend et al., 1996) which might influence the 
motor performance of mice.
MATERIALS AND METHODS
Material
Sodium valproate was obtained in the form of powder for injections (Depakine; Sanofi
Winthrop Industrie, Gentilly, France).
Animals
The transgenic N171-82Q male mice were originally purchased from the Jackson 
Laboratories (Bar Harbor, ME, USA), and were maintained on the B6C3F1 background in our
laboratory. The offspring were genotyped by using a PCR assay on the tail DNA. The mice 
were housed in transgenic cages (at most 5 per cage), with free access to food and water, 
under standard conditions. Male and female transgenic mice and littermates were distributed 
equally between the experimental groups. All animal experiments were carried out in 
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accordance with the NIH Guide for the Care and Use of Laboratory Animals and were 
approved in advance by the local animal care committee.
Treatments
The mice received intraperitoneal injections of sodium valproate (100 mg/kg/day, in a 
volume of 5 ml/kg, dissolved in saline) or the vehicle (in a volume of 5 ml/kg) at the same 
time each day on 5 days per week from 7 weeks of age.
Survival
The transgenic mice were treated with sodium valproate (n=8) or vehicle (n=8), 
according to the regime detailed above, until death occurred. The littermates treated with 
vehicle served as negative controls (n=7) in order to be able to exclude other possible causes 
of death than those due to the presence of the transgene.
Open-field test
The treatment regime was the same as in the examination of survival. We examined 
the spontaneous locomotor activity and the exploration activity of the mice once a week, 2 h 
after the treatment, on the same day each week. The tests were performed at the same time of 
day so as to avoid possible changes due to the diurnal rhythm. Each mouse was placed at the 
centre of a box (48x48x40 cm) and its behaviour during 5 min was recorded with the aid of 
Conducta 1.0 software (Experimetria Ltd., Budapest, Hungary). The ambulation distance, the 
mean velocity, the local time, and the number of rearings were evaluated. To test the possible 
effects of valproate on the spontaneous locomotor activity, wild-type B6C3F1 mice were 
divided into two groups (n=8 in each group), which received valproate or vehicle for 9 weeks 
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according to the treatment regime detailed above. Open-field tests were performed once a 
week, similarly as in the former experiment.
HPLC measurements
In week 9 of treatment, the valproate-treated and control wild-type mice were 
decapitated and the brains were rapidly removed and placed on an ice-cooled plate for 
dissection of the striatum. After dissection, the samples were stored at -70 °C until 
measurements. The striata were weighed and were then manually homogenized in an ice-
cooled solution (250 μl) comprising perchloric acid (7.2 μl; 70% w/w), sodium metabisulfite 
(1 μl; 0.1 M), disodium ethylenediaminetetraacetate (1.25 μl; 0.1 M) and distilled water 
(240.55 μl) for 1 min in a homogenization tube. The content of the homogenization tube was 
quantitatively washed into a test tube with the used solution to give a final volume of 2 ml, 
which was centrifuged at 4,000 g for 30 min at 4 °C. From the supernatant, 250 μl was 
transferred to a test vial, and dopamine and its metabolites, 3,4-dihydroxyphenylacetic acid 
(DOPAC) and homovanillic acid (HVA) were analysed by reversed-phase chromatography, 
using an Agilent 1100 high performance liquid chromatography (HPLC) system (Agilent 
Technologies, Santa Clara, CA, USA) combined with a Model 105 electrochemical detector 
(Precision Instruments, Marseille, France) under isocratic conditions. In brief, the working 
potential of the detector was set at +750 mV, using a glassy carbon electrode and an Ag/AgCl 
reference electrode. The mobile phase containing sodium dihydrogenphosphate (75 mM), 
sodium octylsulfate (2.8 mM) and disodium ethylenediaminetetraacetate (50 μM) was 
supplemented with acetonitrile (10% v/v) and the pH was adjusted to 2.8 with phosphoric acid
(85% w/w). The mobile phase was delivered at a rate of 1 ml/min at 40 °C onto the reversed-
phase column (HR-80 C18, 80x4.6 mm, 3 μm particle size; ESA Biosciences, Chelmsford, 
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MA, USA) after passage through a pre-column (Hypersil ODS, 20x2.1 mm, 5 μm particle 
size; Agilent Technologies, Santa Clara, CA, USA). Ten-microlitre aliquots were injected by 
the autosampler with the cooling module set at 4 °C.
The signals captured by the Model 105 electrochemical detector were converted by an 
Agilent 35900E dual-channel interface and the chromatograms were evaluated by 
ChemStation Rev.1.10.02 software (Agilent Technologies, Santa Clara, CA, USA).
Statistical analysis
Survival data were analysed by using Kaplan-Meier survival curves and the Mantel-
Cox log rank test. For the statistical evaluation of the data in the behaviour tests and 
biochemical analyses, we used the independent t test when 2 groups were involved, and 
analysis of variance followed by Fisher’s LSD post hoc test (StatView 4.53 for Windows, 
Abacus Concepts Inc., Berkeley, CA, USA) when there were more than 2 groups.
RESULTS
Survival
Valproate administered intraperitoneally in a dose of 100 mg/kg on 5 days per week 
from the age of 7 weeks significantly increased the mean survival time of the transgenic mice 
from 109.8 ± 9.7 days to 144.3 ± 7.9 days, i.e. by 31.4% (p < 0.05; Fig. 1).
Behavioural tests
The monitored parameters indicated that mild improvements were already observed in 
the valproate-treated group at 9 weeks of age (week 3 of treatment), and the changes became 
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significant by 12 weeks of age (week 6 of treatment). Thus, as concerns the spontaneous 
locomotor activity at 12 weeks of age (week 6 of treatment), valproate significantly increased 
the ambulation distance (p < 0.001) [F(2,20) = 7.87, p < 0.01] and the mean velocity during 
ambulation (p < 0.001) [F(2,20) = 12.29, p < 0.001], and significantly decreased the local 
time (p < 0.001) [F(2,20) = 10.55, p < 0.001] of the transgenic mice as compared with those 
of the untreated transgenic animals (Fig. 2a, c, e). Furthermore, from the aspect of the 
exploratory behaviour, the treatment significantly increased the number of rearings (p < 0.05) 
[F(2,20) = 6.91, p < 0.01] which was reduced in the transgenic animals (p < 0.01; Fig. 2g). 
The increase in spontaneous locomotor activity was also significant as compared with the 
wild-type mice both in the ambulation distance (p < 0.05) and in mean velocity during 
ambulation (p < 0.01). At 15 weeks of age (week 9 of treatment), the differences in 
ambulation distance and mean velocity during ambulation were not significant, due to an 
increase in the standard deviation. However, the significant differences in local time (p < 
0.001) [F(2,20) = 17.78, p < 0.001] and rearing count (p < 0.05) [F(2,20) = 11.41, p < 0.001] 
still remained between the valproate-treated and untreated transgenic animals. In the applied 
dose, valproate did not influence either the spontaneous locomotor activity or the exploratory 
behaviour of the wild-type mice (Fig. 2b, d, f, h).
HPLC measurements
Valproate, administered intraperitoneally in a dose of 100 mg/kg on 5 days per week 
for 9 weeks did not induce significant changes in the striatal dopamine (Fig. 3a), DOPAC 
(Fig. 3b) or HVA (Fig. 3c) levels.
DISCUSSION
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Although the prevalence of HD is rather low (~5/100 000; Folstein et al., 1987; Evers-
Kiebooms et al., 2002), the disease displays a progressive nature and certainly ends in death. 
It is known that a definite single mutation leads to the development of the disease (the best 
example of trinucleotide repeat expansion disorders), but many questions remain to be 
answered. The pathomechanism must be thoroughly explored, and effective new drugs with 
higher therapeutic value must be developed. At present, only symptomatic therapy is 
available, with neuroleptics, dopamine-depleting agents, antidepressants, antiglutamatergic 
drugs, GABA agonists, antiepileptics, acetylcholinesterase inhibitors and the botulinum toxin 
(reviewed by Adam and Jankovic, 2008). A number of agents have proved protective in 
transgenic models, and have recently been tested in early-phase clinical trials. Depending on 
the molecular mechanism of their effect, the aims mostly involve the inhibition of 
transcription and histone deacetylation, the achievement of marked antioxidant and 
antiexcitotoxic effects, improvement of the mitochondrial function and the prevention of an 
energy impairment (reviewed by Hersch and Ferrante, 2004). The therapeutic potency of 
HDACi molecules is well supported by the fact that suberoylanilide hydroxamic acid with 
HDACi activity markedly ameliorated the motor performance in the R6/2 transgenic mouse 
model of HD (Hockley et al., 2003). Some other HDACi molecules, such as sodium butyrate 
(Ferrante et al., 2003), phenylbutyrate (Gárdián et al., 2005) and pimelic diphenylamide 
HDACi (HDACi 4b; Thomas et al., 2008), have also proved protective in transgenic mouse 
models of HD.
In our experiments, we used the N171-82Q transgenic mouse model of HD, in which 
the developing motor symptoms (Klivényi et al., 2006) are clearly observed. Valproate 
increased the survival time of the transgenic mice significantly (by 31.4%). This elevation is 
noteworthy, as phenylbutyrate with proved HDACi activity lengthened the survival by 23% 
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(Gárdián et al., 2005). Although a reduced number of animals has been included in our study 
(n=8 in both the valproate-treated and the untreated transgenic groups) compared with the 
experiment with phenybutyrate (n=24 in the treated and n=12 in the untreated transgenic 
group), the differences caused by valproate treatment are clearly significant and correspond 
well to our behaviour data and the characteristic of the survival curves can be well studied. 
Nevertheless the experimental findings of these studies can only be cautiously judged due to 
the differences in the number of animals. As regards the spontaneous locomotor activity 
observed in the open-field test, valproate exerted a significant protective effect at 12 weeks of 
age (week 6 of treatment), and as regards the ambulation distance and mean velocity during 
ambulation, the treatment caused significant increases in the transgenic animals as compared 
with the untreated wild-type mice, too. It is worth noting here that there was no detectable 
side-effect of the treatment in the wild-type mice as concerns the spontaneous locomotor 
activity; only the number of rearings was moderately elevated. Thus, as we did not observe a 
similar difference between the treated and the untreated wild-type mice, the considerable 
increase in locomotion mentioned above is probably due to the combined effect resulting from
the treatment and the presence of the transgene. Accordingly, the phenomenon can be 
explained in that there are regional differences in the effect of valproate on the GABA levels 
in certain brain areas. For example, there is a considerable elevation in midbrain regions such 
as the substantia nigra (Iadarola et al., 1979; Löscher and Vetter, 1985), the reticular part of 
which is an important part of both direct and indirect pathways of the basal ganglia circuitry. 
In HD, the function of the indirect pathway deteriorates first, while the direct pathway 
remains intact in the early stages (reviewed by Ramaswamy et al., 2007), resulting in 
hyperkinetic movements in humans. The treatment probably shifts the function of the direct 
pathway by elevating the GABA level in the substantia nigra pars reticulata with decreased 
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inhibition of the thalamus, resulting in increased locomotion. It is also worth mentioning that 
chronic valproate treatment did not influence the striatal levels of dopamine and its 
metabolites, which would also have influenced the motor performance. Preliminary 
examinations on brain pathology by means of cresyl violet staining and anti-huntingtin 
immunohistochemistry indicate that the cellular atrophy was present in treated animals, but its
extent was lower than that of untreated transgenic mice (data not shown). These data are 
consistent with the findings in studies with other HDACis, but valproate does not seem to 
exert such pronounced effects as those substances. Contrary to the previous studies with 
HDACi molecules, where the huntingtin aggregate deposition was not altered, our provisory 
data suggest that valproate treatment diminished the striatal anti-huntingtin immunoreactivity 
(examined with EM48 antibody). This phenomenon might be explained in that the 
pharmacological activity of valproate is more complex than its effects can be interpreted 
solely upon its HDACi activity.
In the 1970s, several clinical trials were carried out with valproate, usually with the 
aim amelioration of the choreiform movements, but without any positive effect (Bachman et 
al., 1977; Pearce et al., 1977; Symington et al., 1978). In the present decade, two studies have 
revealed that valproate is beneficial in monotherapy in the treatment of myoclonus in HD 
(Saft et al., 2006) and in combination therapy with olanzapine in the treatment of psychosis 
and movement disorders related to HD (Grove et al., 2000).
In summary, the beneficial effects of valproate in our experiments are probably due to 
its complex activity, i.e. the increases in GABAergic function, and antiexcitotoxic and 
HDACi effects. However, we should be cautious with the interpretation of the results, 
especially when the findings of previous clinical trials are considered. The treatment with 
valproate merely delayed the onset of the symptoms, and did not alter the characteristics of 
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the survival curve; its effect therefore seems to be mainly symptomatic, which is supported by
the preliminary findings on brain pathology. Furthermore, we began our experiments before 
the onset of motor symptoms, whereas the earlier studies were carried out on patients with 
manifest clinical symptoms of HD. Nevertheless, it is worth considering the design of further 
preclinical studies with valproate and upon reinforcing results the set up of new clinical trials 
based on a well-planned treatment regime, using valproate in monotherapy or in combination 
therapy with a high number of participating patients.
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FIGURE LEGENDS
Fig. 1. Kaplan-Meier survival curves of control and valproate-treated N171-82Q transgenic
mice. The treatment with valproate significantly increased the survival duration relative to the
controls. (n=8; p < 0.05, Mantel-Cox log rank test)
Fig.  2.  The  effects  of  valproate  treatment  on  the  spontaneous  locomotor  activity  and
exploratory behaviour in the open-field test. Valproate significantly increased the ambulation
distance (a; p < 0.001), the mean velocity (c; p < 0.001) and the number of rearings (g; p <
0.05), and significantly decreased the local time (e; p < 0.001) of the transgenic mice at the
age of 12 weeks (week 6 of treatment) as compared with the transgenic controls from which
the  differences  in  local  time  (p  <  0.001)  and  in  the  number  of  rearings  (p  <  0.05)  still
remained significant at the age of 15 weeks (week 9 of treatment). As compared with the
wild-type  mice,  the group means for the valproate-treated  animals  were also significantly
higher as concerns the ambulation distance (p < 0.05) and velocity (p < 0.01); nevertheless,
the valproate treatment of the wild-type mice did not lead to any significant difference as
compared with the control group (b, d, f, h). (n=8 wild-type mice, the numbers of mice in the
transgenic  groups  are  presented  on the  bar  charts;  tg:  transgenic;  wt:  wild-type;  data  are
means + S.E.M.; *p < 0.05; **p < 0.01; ***p < 0.001)
Fig. 3. Striatal  dopamine,  DOPAC and HVA concentrations of valproate-treated wild-type
mice  after  9  weeks  of  treatment.  Valproate  treatment  did  not  significantly  influence  the
striatal level of dopamine (a), or DOPAC (b), or HVA (c) as compared with the untreated
wild-type mice. (n=8; data are means + S.E.M.)
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